• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23806 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Adelaide Health Technology Assessment (AHTA) National Evidence-Based Guideline on Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes: Technical Report
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (Addendum to Commission A14-25)]
2015     Health Quality Ontario (HQO) Aerobic exercise training in patients with heart failure: a rapid review
2015     Health Council of the Netherlands Gezondheidsraad (GR) Population Screening Act: risk stratification based on familial risk of bowel cancer
2015     Andalusian Health Technology Assessment Area (AETSA) FDG-PET/CT and SPECT for cancer staging.
2015     Adelaide Health Technology Assessment (AHTA) Systematic review of the human health effects of wind farms
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-26 (empagliflozin)]
2015     Health Quality Ontario (HQO) Home-based exercise programs in heart failure: a rapid review
2015     Health Council of the Netherlands Gezondheidsraad (GR) Thiotepa - health-based calculated occupational cancer risk values
2015     Andalusian Health Technology Assessment Area (AETSA) Focal therapy in localized prostate cancer: irreversible electroporation, HIFU and holmium laser
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     Health Quality Ontario (HQO) Medication reconciliation at discharge: a rapid review
2015     Health Quality Ontario (HQO) Colon capsule endoscopy for the detection of colorectal polyps: an evidence-based analysis
2015     Andalusian Health Technology Assessment Area (AETSA) Utility of QF_PCR in prenatal diagnosis of fetal aneuploidies
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Alipogene tiparvovec - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     Health Quality Ontario (HQO) Physical activity counselling: a rapid review
2015     Institute of Health Economics (IHE) Post policy implementation review (PPIR) of rapid fetal fibronectin testing for preterm labour in Alberta
2015     Agency for Healthcare Research and Quality (AHRQ) Management of insomnia disorder
2015     Andalusian Health Technology Assessment Area (AETSA) Magnetic growth rods in early onset scoliosis with diverse etiology
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-28 (apixaban)]
2015     Health Quality Ontario (HQO) Ultrafiltration in heart failure: a rapid review
2015     Institut national d'excellence en sante et en services sociaux (INESSS) Effectiveness of child maltreatment risk assessment tools
2015     Agency for Healthcare Research and Quality (AHRQ) Health information exchange
2015     Malaysian Health Technology Assessment (MaHTAS) Kangaroo mother care
2015     Andalusian Health Technology Assessment Area (AETSA) Stentoplasty effectiveness and safety for the treatment of osteoporotic vertebral fractures
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lurasidone - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Intraoperative ultrasound-guided breast-conserving surgery]
2015     Andalusian Health Technology Assessment Area (AETSA) Active immunotherapy for lung cancer. Systematic review.
2015     Gesundheit Osterreich GmbH (GOeG) [Pharmaceutical stroke prevention in atrial fibrillation]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-31 (daclatasvir)]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Complex wound treatment: negative pressure therapy]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Simoctocog alfa - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     NIHR Health Technology Assessment programme Dual-chamber pacemakers for treating symptomatic bradycardia due to sick sinus syndrome without atrioventricular block: a systematic review and economic evaluation
2015     NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation and surgery for varicose veins: results from the Comparison of LAser, Surgery and foam Sclerotherapy (CLASS) randomised controlled trial
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Notice on equal access to physiotherapy services. Part I - Review of the evidence on the effectiveness and cost of psychotherapy compared to treatment of adults with anxiety and depressive disorders]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aflibercept (Addendum to Commission A14-32)]
2015     NIHR Health Technology Assessment programme Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Notice on equal access to physiotherapy services. Part II - Analysis of the terms and conditions of access to psychotherapy for the treatment of adults with depressive disorders and anxiety]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods]
2015     NIHR Health Technology Assessment programme Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation
2015     NIHR Health Technology Assessment programme Calculating when elective abdominal aortic aneurysm repair improves survival for individual patients: development of the Aneurysm Repair Decision Aid and economic evaluation
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Notice of the impact of the decrease of the maximum payable amount for the class of proton pump inhibitors]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ataluren - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2015     National Institute for Health and Care Excellence (NICE) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. NICE technology appraisal guidance 329
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Levels of medical intervention -- levels of care]
2015     Malaysian Health Technology Assessment (MaHTAS) Capsule endoscopy for colorectal cancer (CRC) screening
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vildagliptin - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Sofosbuvir for treating chronic hepatitis C. NICE technology appraisal guidance 330
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Review process of matricial requirements for acute care facilities in the Quebec traumatology network]
2015     Malaysian Health Technology Assessment (MaHTAS) Health risk Assessment (HRA) module for breast cancer
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ledipasvir/sofosbuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. NICE technology appraisal guidance 333
2015     The Netherlands Organisation for Health Research and Development (ZonMw) [Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients: the Dutch Convective Transport Study (CONTRAST)]
2015     NIHR Health Technology Assessment programme Clinical trial metadata: Defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the NIHR Health Technology Assessment Programme
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Investigation, treatment and monitoring algorithms for prostate cancer]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sipuleucel-T (Addendum to Commission A14-38)]
2015     National Institute for Health and Care Excellence (NICE) Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal). NICE technology appraisal guidance 334
2015     NIHR Public Health Research (PHR) programme What is the effect of reduced street lighting on crime and road traffic injuries at night? A mixed-methods study
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guides and glossary for hospital quality reports - Rapid report]
2015     National Institute for Health and Care Excellence (NICE) Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. NICE technology appraisal guidance 335
2015     NIHR Health Services and Delivery Research programme Insights from the clinical assurance of service reconfiguration in the NHS: the drivers of reconfiguration and the evidence that underpins it – a mixed-methods study
2015     NIHR Health Services and Delivery Research programme A realist analysis of hospital patient safety in Wales: applied learning for alternative contexts from a multisite case study
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Newborn screening for critical congenital heart disease using pulse oximetry]
2015     National Institute for Health and Care Excellence (NICE) Empagliflozin in combination therapy for treating type 2 diabetes. NICE technology appraisal guidance 336
2015     NIHR Health Technology Assessment programme Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness
2015     NIHR Health Services and Delivery Research programme NHS commissioning practice and health system governance: a mixed-methods realistic evaluation
2015     Health Quality Ontario (HQO) Mitral valve clip for treatment of mitral regurgitation: OHTAC recommendation
2015     Adelaide Health Technology Assessment (AHTA) Screening for coronary artery disease using CT calcium scoring
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pasireotide (new therapeutic indication) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Rifaximin for preventing episodes of overt hepatic encephalopathy. NICE technology appraisal guidance 337
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part III: carnitine uptake deficiency (CUD); short-chain acyl-CoA dehydrogenase deficiency (SCADD); very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2015     NIHR Health Services and Delivery Research programme The dynamics of quality: a national panel study of evidence-based standards
2015     Health Quality Ontario (HQO) Mitral valve clip for treatment of mitral regurgitation: an evidence-based analysis
2015     Adelaide Health Technology Assessment (AHTA) Endovascular clot retrieval with thrombolysis for ischaemic stroke
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Objectively derived approach for the development of search strategies in bibliographic databases]
2015     National Institute for Health and Care Excellence (NICE) Omalizumab for previously treated chronic spontaneous urticaria. NICE technology appraisal guidance 339
2015     National Institute for Health and Care Excellence (NICE) VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions. NICE diagnostics guidance 19
2015     NIHR Health Services and Delivery Research programme A national study of practice patterns in UK renal units in the use of dialysis and conservative kidney management to treat people aged 75 years and over with chronic kidney failure
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Reablement for seniors experience a loss of autonomy]
2015     Adelaide Health Technology Assessment (AHTA) Ultra-filtration for patients with decompensated heart failure
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Invitation and fact sheet for breast cancer Screening - Rapid report]
2015     National Institute for Health and Care Excellence (NICE) Ustekinumab for treating active psoriatic arthritis. NICE technology appraisal guidance 340
2015     National Institute for Health and Care Excellence (NICE) Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay). NICE diagnostics guidance 18
2015     NIHR Health Services and Delivery Research programme Using clinical practice variations as a method for commissioners and clinicians to identify and prioritise opportunities for disinvestment in health care: a cross-sectional study, systematic reviews and qualitative study
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Information brief concerning palliative care day centres]
2015     Adelaide Health Technology Assessment (AHTA) Blood and stool biomarker testing for colorectal cancer screening
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Continuous interstitial glucose monitoring (CGM) with real-time measurement devices in insulin-dependent diabetes mellitus]
2015     National Institute for Health and Care Excellence (NICE) Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 341
2015     NIHR Health Services and Delivery Research programme The delivery of chemotherapy at home: an evidence synthesis
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Insulin pumps in the treatment of type 1 diabetes]
2015     NIHR Public Health Research (PHR) programme The impact on health inequalities of approaches to community engagement in the New Deal for Communities regeneration initiative: a mixed-methods evaluation
2015     Adelaide Health Technology Assessment (AHTA) Pressurised intraperitoneal aerosol chemotherapy
2015     Gesundheit Osterreich GmbH (GOeG) [Non-drug prevention and treatment of Alzheimer's dementia and mixed dementia]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 342
2015     NIHR Health Services and Delivery Research programme The management of individuals with enduring moderate to severe mental health needs: a participatory evaluation of client journeys and the interface of mental health services with the criminal justice system in Cornwall
2015     Health Council of the Netherlands Gezondheidsraad (GR) [Population Screening Act: prevalence of gastrointestinal tract disorders studied with a video capsule]
2015     Adelaide Health Technology Assessment (AHTA) High-frequency spinal cord stimulation and dorsal root ganglion stimulation for chronic pain
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     National Institute for Health and Care Excellence (NICE) Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 343